Time Trend in SARS-CoV-2 Seropositivity, Surveillance Detection- and Infection Fatality Ratio until Spring 2021 in the Tirschenreuth County-Results from a Population-Based Longitudinal Study in Germany.
SARS-CoV-2
case fatality ratio
elderly
infection fatality ratio
longitudinal
population-based
senior care homes
seroprevalence
surveillance detection ratio
vaccination
Journal
Viruses
ISSN: 1999-4915
Titre abrégé: Viruses
Pays: Switzerland
ID NLM: 101509722
Informations de publication
Date de publication:
27 05 2022
27 05 2022
Historique:
received:
29
03
2022
revised:
20
05
2022
accepted:
24
05
2022
entrez:
24
6
2022
pubmed:
25
6
2022
medline:
28
6
2022
Statut:
epublish
Résumé
Herein, we provide results from a prospective population-based longitudinal follow-up (FU) SARS-CoV-2 serosurveillance study in Tirschenreuth, the county which was hit hardest in Germany in spring 2020 and early 2021. Of 4203 individuals aged 14 years or older enrolled at baseline (BL, June 2020), 3546 participated at FU1 (November 2020) and 3391 at FU2 (April 2021). Key metrics comprising standardized seroprevalence, surveillance detection ratio (SDR), infection fatality ratio (IFR) and success of the vaccination campaign were derived using the Roche N- and S-Elecsys anti-SARS-CoV-2 test together with a self-administered questionnaire. N-seropositivity at BL was 9.2% (1st wave). While we observed a low new seropositivity between BL and FU1 (0.9%), the combined 2nd and 3rd wave accounted for 6.1% new N-seropositives between FU1 and FU2 (ever seropositives at FU2: 15.4%). The SDR decreased from 5.4 (BL) to 1.1 (FU2) highlighting the success of massively increased testing in the population. The IFR based on a combination of serology and registration data resulted in 3.3% between November 2020 and April 2021 compared to 2.3% until June 2020. Although IFRs were consistently higher at FU2 compared to BL across age-groups, highest among individuals aged 70+ (18.3% versus 10.7%, respectively), observed differences were within statistical uncertainty bounds. While municipalities with senior care homes showed a higher IFR at BL (3.0% with senior care home vs. 0.7% w/o), this effect diminished at FU2 (3.4% vs. 2.9%). In April 2021 (FU2), vaccination rate in the elderly was high (>77.4%, age-group 80+).
Identifiants
pubmed: 35746640
pii: v14061168
doi: 10.3390/v14061168
pmc: PMC9228731
pii:
doi:
Substances chimiques
Antibodies, Viral
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Références
Int J Environ Res Public Health. 2021 Mar 30;18(7):
pubmed: 33808249
Med (N Y). 2021 May 14;2(5):571-572
pubmed: 33842906
Eur J Epidemiol. 2021 Jul;36(7):715-725
pubmed: 34420152
Dtsch Arztebl Int. 2021 Dec 10;118(49):842-843
pubmed: 35264284
Nat Commun. 2021 Jul 19;12(1):4383
pubmed: 34282139
Lancet Infect Dis. 2021 Sep;21(9):1213-1214
pubmed: 34197767
Influenza Other Respir Viruses. 2022 Mar;16(2):204-212
pubmed: 34751488
J Virol. 2021 Jan 13;95(3):
pubmed: 33144321
N Engl J Med. 2021 Feb 4;384(5):403-416
pubmed: 33378609
Euro Surveill. 2021 Aug;26(34):
pubmed: 34448448
Vaccines (Basel). 2022 Feb 18;10(2):
pubmed: 35214782
Epidemiol Infect. 2020 Jun 29;148:e130
pubmed: 32594937
Epidemiol Infect. 2020 Oct 13;148:e252
pubmed: 33046173
N Engl J Med. 2020 Dec 31;383(27):2603-2615
pubmed: 33301246
J Gen Virol. 2020 Aug;101(8):791-797
pubmed: 32430094
Science. 2021 Apr 9;372(6538):
pubmed: 33658326
Lancet. 2021 Mar 20;397(10279):1075-1084
pubmed: 33743869
Infection. 2021 Feb;49(1):75-82
pubmed: 32827125
Eur J Immunol. 2022 Jan;52(1):149-160
pubmed: 34695227
Am J Epidemiol. 2021 Jan 4;190(1):109-115
pubmed: 32803245
Clin Med (Lond). 2021 Jan;21(1):e54-e56
pubmed: 33243836
Euro Surveill. 2020 Jul;25(28):
pubmed: 32700672
BMC Public Health. 2020 Jun 30;20(1):1036
pubmed: 32605549
Nature. 2021 May;593(7858):270-274
pubmed: 33723411
BMC Infect Dis. 2021 Sep 8;21(1):925
pubmed: 34493217
Dtsch Arztebl Int. 2021 Dec 3;118(48):824-831
pubmed: 35191825
Diagnostics (Basel). 2021 Oct 06;11(10):
pubmed: 34679541
Nat Commun. 2021 Apr 9;12(1):2117
pubmed: 33837204
Eur J Epidemiol. 2020 Dec;35(12):1123-1138
pubmed: 33289900
Dtsch Arztebl Int. 2020 Dec 11;117(50):861-867
pubmed: 33295275
Commun Med (Lond). 2022 May 18;2:52
pubmed: 35603305
Nat Commun. 2020 Nov 17;11(1):5829
pubmed: 33203887
Lancet. 2021 Mar 6;397(10277):881-891
pubmed: 33617777
Lancet. 2022 Apr 16;399(10334):1469-1488
pubmed: 35219376
Viruses. 2021 Jun 10;13(6):
pubmed: 34200766